Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Catalyst Biosciences logo

About Catalyst Biosciences Stock (NASDAQ:CBIO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.34
$7.67
52-Week Range
N/A
Volume
32,246 shs
Average Volume
763,526 shs
Market Capitalization
$291.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Stock News Headlines

Catalyst Biosciences Inc trading halted, volatility trading pause
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Catalyst Mutual Funds
See More Headlines

CBIO Stock Analysis - Frequently Asked Questions

Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its quarterly earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07).

Shares of Catalyst Biosciences reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/17/2023
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
Employees
7
Year Founded
2003

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.24 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$790,000.00
Price / Cash Flow
N/A
Book Value
($0.78) per share
Price / Book
N/A

Miscellaneous

Free Float
36,869,000
Market Cap
$291.29 million
Optionable
Optionable
Beta
1.05

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:CBIO) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners